CK Life Sciences Int'l. (Holdings) Management

Management criteria checks 3/4

CK Life Sciences Int'l. (Holdings)'s CEO is Lance Richard Yuen, appointed in Sep 2024, has a tenure of 1.58 years. total yearly compensation is HK$6.88M, comprised of 47.1% salary and 52.9% bonuses, including company stock and options. directly owns 0.024% of the company’s shares, worth $214.41K. The average tenure of the management team and the board of directors is 7.4 years and 7.4 years respectively.

Key information

Lance Richard Yuen

Chief executive officer

HK$6.9m

Total compensation

CEO salary percentage	47.08%
CEO tenure	1.6yrs
CEO ownership	0.02%
Management average tenure	7.4yrs
Board average tenure	7.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Lance Richard Yuen's remuneration changed compared to CK Life Sciences Int'l. (Holdings)'s earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2025	n/a	n/a	-HK$187m
Sep 30 2025	n/a	n/a	-HK$233m
Jun 30 2025	n/a	n/a	-HK$278m
Mar 31 2025	n/a	n/a	-HK$202m
Dec 31 2024	HK$7m	HK$3m	-HK$127m

Compensation vs Market: Lance Richard's total compensation ($USD878.33K) is below average for companies of similar size in the US market ($USD3.52M).

Compensation vs Earnings: Insufficient data to compare Lance Richard's compensation with company performance.

CEO

Lance Richard Yuen (59 yo)

1.6yrs

Tenure

HK$6,878,000

Compensation

Mr. Lee Yuen, also known as Lance Richard, is Executive Director, Vice President & Chief Executive Officer of CK Life Sciences Int'l. (Holdings) Inc. from September 20, 2024. Mr. Yuen joined the Group in S...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Tzar Kuoi Li	Executive Chairman	24yrs	HK$125.00k	0.023% $ 209.7k
Lee Yuen	VP, CEO & Executive Director	1.6yrs	HK$6.88m	0.024% $ 214.4k
Ying Choi Yu	Executive Deputy Chairman	1.6yrs	HK$15.26m	0.023% $ 209.7k
Hing Lam Kam	President & Executive Director	23.8yrs	HK$3.08m	0.041% $ 365.9k
Tak Chuen IP	Senior VP	no data	HK$1.10m	0.023% $ 209.7k
Kean Meng Toh	VP, Chief Scientific Officer & Executive Director	7.4yrs	HK$6.44m	no data
Wun Lam Wong	Chief Financial Officer	no data	no data	no data
Pak To Wu	Chief Operating Officer of Global Operations	no data	no data	no data
Yau Wong	General Manager of Human Resources & Administration	no data	no data	no data
Ching Sze Chiu	General Counsel	no data	no data	no data
Sze Ho	Vice President of Corporate Development	no data	no data	no data
Wai Che Tong Barnes	Chief Corporate Affairs Officer	no data	no data	no data

7.4yrs

Average Tenure

60.5yo

Average Age

Experienced Management: CKLS.F's management team is seasoned and experienced (7.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Tzar Kuoi Li	Executive Chairman	24yrs	HK$125.00k	0.023% $ 209.7k
Lee Yuen	VP, CEO & Executive Director	1.6yrs	HK$6.88m	0.024% $ 214.4k
Ying Choi Yu	Executive Deputy Chairman	1.6yrs	HK$15.26m	0.023% $ 209.7k
Hing Lam Kam	President & Executive Director	no data	HK$3.08m	0.041% $ 365.9k
Tak Chuen IP	Senior VP	no data	HK$1.10m	0.023% $ 209.7k
Kean Meng Toh	VP, Chief Scientific Officer & Executive Director	7.4yrs	HK$6.44m	no data
Eva Kwok	Independent Non-Executive Director	23.8yrs	HK$100.00k	0.0021% $ 18.6k
Keith Frankel	Co-Chairman of Vitaquest International LLC	no data	no data	no data
Peter Peace Tulloch	Non-Executive Director	24yrs	HK$75.00k	0.011% $ 97.8k
Kai Cheong Kwan	Independent Non-executive Director	11.1yrs	HK$155.00k	no data
Donald Jeffrey Roberts	Independent Non-Executive Director	5.8yrs	HK$205.00k	no data
Joseph Paul Tighe	Independent Non-Executive Director	6.8yrs	HK$205.00k	no data

7.4yrs

Average Tenure

71yo

Average Age

Experienced Board: CKLS.F's board of directors are considered experienced (7.4 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/04/21 00:21
End of Day Share Price	2026/01/23 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CK Life Sciences Int'l., (Holdings) Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.